Pay in 4 interest-free payments of $5.78 Learn more
Ships within 48 hours · Estimated delivery Sep 26 - Oct 1
A Canadian company cleared a major regulatory hurdle, Novo Nordisk dramatically cut US Wegovy pricing, and the pan-Canadian Pharmaceutical Alliance laid the groundwork for generic pricing
RUO classification means the material is intended for in-vitro research, assay development, and pre-clinical laboratory work not for diagnostic, therapeutic, or human-administration purposes
The most commonly prescribed options include Semaglutide (marketed as Wegovy or Ozempic) and Liraglutide (marketed as Saxenda), which differ in dosing frequency and strength
Net Loss Per Share The Company calculates basic and diluted net loss per share attributable to common stockholders in conformity with the two-class method required for participating securities
US$ 26.27
US$ 26.19
US$ 23.26
US$ 20.90
US$ 27.69
